Form 4 for ETON Eton Pharmaceuticals, Inc.
Accepted 2025-12-12 00:00:00 ET · period of report 2025-12-11 · accession 0001437749-25-037743 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-12 | 2025-12-12 | ETON | Gruber James R. | CFO | F - Tax | $16.99 | -4,542 | 215.7K | -2% | -$77.2K |
| D | 2025-12-12 | 2025-12-11 | ETON | Gruber James R. | CFO | A - Grant | $0.00 | +5,502 | 210.3K | +3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-12 | F | D | 4,542 | $16.99 | 215,713 | D | — | — | (F1) Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units. (F3) The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. (F2) The shares were sold in multiple trades at prices ranging from $16.94 to $17.07. The price reported above reflects the weighted average sales price. |
| 2 | Derivative | Restricted Stock Units | 2025-12-11 | A | A | 5,502 | $0.00 | 210,255 | D | — · — to — | 5,502 Common Stock | (F4) Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. (F5) The restricted stock units vest immediately as of the award date. |